Marshall Wace North America L.P. purchased a new stake in Catalent Inc (NASDAQ:CTLT) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 136,220 shares of the company’s stock, valued at approximately $4,767,000. Marshall Wace North America L.P. owned approximately 0.11% of Catalent as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Teachers Advisors LLC raised its position in Catalent by 3.0% in the fourth quarter. Teachers Advisors LLC now owns 164,748 shares of the company’s stock valued at $4,442,000 after buying an additional 4,823 shares in the last quarter. Capstone Asset Management Co. raised its position in Catalent by 3.4% in the first quarter. Capstone Asset Management Co. now owns 9,900 shares of the company’s stock valued at $280,000 after buying an additional 330 shares in the last quarter. Louisiana State Employees Retirement System raised its position in Catalent by 2.3% in the first quarter. Louisiana State Employees Retirement System now owns 31,500 shares of the company’s stock valued at $892,000 after buying an additional 700 shares in the last quarter. Nationwide Fund Advisors raised its position in Catalent by 8.0% in the first quarter. Nationwide Fund Advisors now owns 291,103 shares of the company’s stock valued at $8,244,000 after buying an additional 21,540 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Catalent by 115.7% in the first quarter. Acadian Asset Management LLC now owns 5,847 shares of the company’s stock valued at $166,000 after buying an additional 3,136 shares in the last quarter.

Catalent Inc (NASDAQ:CTLT) opened at 39.37 on Thursday. Catalent Inc has a 12 month low of $21.83 and a 12 month high of $40.44. The company has a 50-day moving average of $35.14 and a 200-day moving average of $32.37. The company has a market cap of $4.93 billion and a price-to-earnings ratio of 45.25.

Catalent (NASDAQ:CTLT) last posted its earnings results on Monday, August 28th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.57 by $0.08. The firm had revenue of $616.90 million during the quarter, compared to the consensus estimate of $547.48 million. Catalent had a return on equity of 16.95% and a net margin of 4.88%. The business’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period last year, the company earned $0.52 earnings per share. Analysts predict that Catalent Inc will post $1.60 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/marshall-wace-north-america-l-p-buys-new-position-in-catalent-inc-ctlt/1533332.html.

Several equities analysts have recently commented on CTLT shares. William Blair upgraded shares of Catalent from a “market perform” rating to an “outperform” rating in a research report on Friday, May 5th. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “sell” rating in a research report on Tuesday, May 9th. Bank of America Corporation restated a “buy” rating and set a $37.00 price target (up previously from $32.00) on shares of Catalent in a research report on Wednesday, May 17th. BidaskClub lowered shares of Catalent from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $45.00 price target on shares of Catalent in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $35.88.

In other Catalent news, SVP Christine Dolan sold 745 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $34.85, for a total value of $25,963.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).

Institutional Ownership by Quarter for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.